

# Resource Summary Report

Generated by [RRID](#) on Aug 7, 2026

## Mouse Anti-EGF Receptor, phospho (Tyr1068) Monoclonal Antibody, Unconjugated, Clone 1H12

RRID:AB\_331792

Type: Antibody

---

### Proper Citation

Cell Signaling Technology Cat# 2236, RRID:AB\_331792

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_331792](http://antibodyregistry.org/AB_331792)

**Proper Citation:** Cell Signaling Technology Cat# 2236, RRID:AB\_331792

**Target Antigen:** EGF Receptor, phospho (Tyr1068)

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Applications: W, IP. Consolidation on 10/2018: AB\_10077603, AB\_10078790, AB\_331792, AB\_331793.

**Antibody Name:** Mouse Anti-EGF Receptor, phospho (Tyr1068) Monoclonal Antibody, Unconjugated, Clone 1H12

**Description:** This monoclonal targets EGF Receptor, phospho (Tyr1068)

**Target Organism:** rat, mouse, human

**Clone ID:** Clone 1H12

**Antibody ID:** AB\_331792

**Vendor:** Cell Signaling Technology

**Catalog Number:** 2236

**Record Creation Time:** 20250820T042414+0000

**Record Last Update:** 20250820T185231+0000

---

### Ratings and Alerts

No rating or validation information has been found for Mouse Anti-EGF Receptor, phospho (Tyr1068) Monoclonal Antibody, Unconjugated, Clone 1H12.

No alerts have been found for Mouse Anti-EGF Receptor, phospho (Tyr1068) Monoclonal Antibody, Unconjugated, Clone 1H12.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 9 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Lam D, et al. (2026) Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function. *Cancers*, 18(3).

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. *Cancer discovery*, 16(1), 81.

Chen S, et al. (2025) LncRNA EUDAL shapes tumor cell response to hypoxia-induced constitutive EGFR activation and promotes chemoresistance in oral cancer. *International journal of oral science*, 17(1), 64.

Riley AK, et al. (2024) The deubiquitinase USP9X regulates RIT1 protein abundance and oncogenic phenotypes. *iScience*, 27(8), 110499.

Perez Verdaguer M, et al. (2022) Time-resolved proximity labeling of protein networks associated with ligand-activated EGFR. *Cell reports*, 39(11), 110950.

Franco Nitta C, et al. (2021) EGFR transactivates RON to drive oncogenic crosstalk. *eLife*, 10.

Dabelsteen S, et al. (2020) Essential Functions of Glycans in Human Epithelia Dissected by a CRISPR-Cas9-Engineered Human Organotypic Skin Model. *Developmental cell*, 54(5), 669.

Woolston A, et al. (2019) Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. *Cancer cell*, 36(1), 35.

Choi HJ, et al. (2019) CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling. *EMBO reports*, 20(10), e48058.